EYPT News and Press, EyePoint Pharmaceuticals Inc. From 05/18/23

2023-05-18 10:52:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement...

–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical ...

2023-05-12 10:10:00 ET Vancouver, Kelowna, Delta, BC - May 12, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, mining, retail and entertainment. Today's stocks have been...

2023-05-03 23:48:03 ET EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Results Conference Call May 03, 2023 08:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating...

2023-05-03 13:01:00 ET EyePoint Pharmaceuticals ( NASDAQ: EYPT ) stock rose ~20% on Wednesday after Q1 results surpassed analysts estimates. Net loss was largely flat at -$21.16M, compared to -$20.98M in Q1 2022. Total revenue fell -17.3% Y/Y to $7.68M but beat estimates...

2023-05-03 07:10:13 ET EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q1 GAAP EPS of -$0.56 beats by $0.13 . Revenue of $7.68M (-17.4% Y/Y) beats by $0.11M . The company expects the cash, cash equivalents and investments on hand at March 31, 2023 and ...

– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 – Enrollment ahead of schedule in the Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-...

2023-05-02 12:47:41 ET EyePoint Pharmaceuticals ( NASDAQ: EYPT ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is -$0.66 (-17.9% Y/Y) and the consensus Revenue Estimate is $7.57M (-18.6% Y/Y). Over th...

2023-05-02 08:45:56 ET Palm Beach, FL – May 2, 2023 – FinancialNewsMedia.com News Commentary – The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the rising prevalence of ...

WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:...